Tekla Life Sciences Investors Stock News

The

Geode Capital Management LLC raised its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 16.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exc

During the last few months, most closed-end funds have been hit hard. Moreover, their recovery had lagged the broader market, but more recently, they have been

MML Investors Services LLC boosted its position in shares of Tekla Healthcare Investors (NYSE:HQH) by 10.9% in the first quarter, according to the company in its most recent 13F filing with the Securi

The

Rockefeller Capital Management L.P. bought a new stake in Tekla Healthcare Investors (NYSE:HQH) during the first quarter, according to its most recent 13F filing with the SEC. The institutional invest

On June 8, 2020, Tekla Healthcare Opportunities Fund declared its monthly cash distribution of $0.1125 per share. The record date for the monthly cash distribution is June 19, 2020 and the payable dat

Boston-based hearing loss gene therapy biotech Akouos is gunning for a $100 million IPO amid a near invulnerable market for public-seeking biotechs.

Gilead and Galapagos have presented long-term midphase data on filgotinib in patients with active psoriatic arthritis. The analysis shows responses seen at 16 weeks were sustained out to 52 weeks afte

When Nimbus Therapeutics set up shop in 2009, it had to convince the industry—including its founding chief scientific officer—that virtual drug discovery could be a viable approach. Now, Nimbus is

Just a few months after GlaxoSmithKline penned a $50 million deal with biotech Immatics for its T-cell work, the executive running the Big Pharma’s cancer cell therapy unit is upping sticks to join

After swinging the ax on staffers last year and gaining a new CEO a few months back, Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Phar

Gilead and Galapagos have released 52-week clinical trial data showing the durability of filgotinib in rheumatoid arthritis patients. The update comes as the partners close in on a FDA approval that w

Athira Pharma changed its name last year to reflect its focus on regenerative medicine. Now, it’s snagged $85 million to advance those medicines, which includes bankrolling a phase 2/3 trial in Alzh

Since it launched in 2018, Accent Therapeutics has busied itself discovering new targets for cancer drugs in the space of RNA-modifying proteins. But the time for lying low is over—just weeks after